37 results about "Elongation factor" patented technology

The invention relates to a fusion protein, an immunogenic composition and a recombinant degenerate vaccine for preventing and treating infection of various pathogenic streptococci, as well as a molecular architecture design, application and the like. According to the invention, three immune antigens, namely an elongation factor Tu (Tuf), a molecular chaperone DnaK and an elongation factor G (fusA), are screened, and it is proved that fusion protein molecules of the three antigens can significantly inhibit tissue lesions caused by infection of different serotypes and different types of streptococci, have good immunogenicity, play roles in immune protection and effective prevention and treatment, and have good application prospects. The bacillus subtilis has the characteristics of broad-spectrum and high-efficiency prevention of streptococcus bacterial infection, and has a wide application prospect.

The invention belongs to the technical field of plant genetic engineering, and particularly relates to an elongation factor subunit OsRAV9 gene for regulating and controlling resistance of rice to rice blast and application of the elongation factor subunit OsRAV9 gene. The elongation factor subunit OsRAV9 gene induced to express by magnaporthe oryzae is screened, and the nucleotide sequence of the elongation factor subunit OsRAV9 gene is as shown in SEQ ID NO: 1; the sequence of the protein coded by the gene is as shown in SEQ ID NO: 2. By means of agrobacterium tumefaciens-mediated transformation, an OsRAV9 over-expression transgenic strain and a CRISPR / Cas9 mutant strain are obtained. The rice blast inoculation identification on the transgenic material finds that the resistance of the OsRAV9 over-expression strain to the rice blast is enhanced, and the mutant strain is more susceptible to the rice blast bacteria, which indicates that the OsRAV9 is a positive regulation factor of the rice to the rice blast resistance. The OsRAV9 gene plays a positive regulation role in the rice blast resistance, and the resistance of rice to the rice blast can be remarkably improved by over-expression of the gene.

The invention discloses a biochemical multi-item liquid quality control product containing 67 analytes and a preparation method of the biochemical multi-item liquid quality control product, and belongs to the technical field of biochemical quality control products, non-analytes of the quality control product comprise a cryoprotectant compound with the addition amount of 0.1-1%, the cryoprotectant compound comprises antifreeze protein and a protein stabilizer, and the antifreeze protein and the protein stabilizer are added into the quality control product. The mass ratio of the antifreeze protein to the protein stabilizer is (0.1: 1)-(0.5: 1); the biochemical multi-liquid quality control product is frozen liquid. According to the invention, antifreeze protein and elongation factor 1-alpha homologous protein cooperate through physical-chemical dual pathways, complete-cycle protection is provided for protein and enzyme in a quality control product aiming at'mechanical factor 'and'oxidation factor' of freezing damage, and inter-batch consistency and storage stability can be improved; and errors caused by redissolution can be avoided, the detection convenience and accuracy of inspectors are greatly improved, and the labor and time cost of a laboratory is reduced.

The invention discloses a gene editing system and a construction and evaluation method, and relates to the technical field of biology. A gene promoter for coding an EF1-alpha extension factor in medicago sativa is adopted to drive Cas9 expression, a Cas9 gene sequence is optimized according to codon preference for coding amino acid in medicago sativa, an improved CRISPR2.0 system is obtained, and a carrier CRISPR2.0-1 * MsEF1-alpha P:: Opt-Cas9 is constructed; a promoter sequence of an EF1-alpha elongation factor of the high-expression gene is shown as SEQ ID NO: 1, and a coding sequence of the optimized CAS9 gene is shown as SEQ ID NO: 2. The evaluation method of the gene editing effectiveness of the gene editing system comprises the following steps: co-expressing the system in tobacco leaves and establishing the gene editing evaluation system by relying on alfalfa transgenic hairy roots. The editing precision is improved, and the genome mutation risk is reduced.

The embodiment of the invention discloses application of an anti-toxoplasma gondii elongation factor monoclonal antibody in toxoplasma gondii detection and a detection method, and belongs to the technical field of toxoplasma gondii detection, a toxoplasma gondii elongation factor is EF-1alpha, and early diagnosis and discovery of toxoplasma gondii infection are crucial to control of the disease. The monoclonal antibody for resisting the toxoplasma gondii elongation factor EF-1 alpha is an antibody which has great potential to be applied to diagnosis of toxoplasmosis, the expression of the toxoplasma gondii elongation factor 1-alpha is highly conservative, and the monoclonal antibody plays an important role in pathogenesis of parasites and host cell invasion. The monoclonal antibody for resisting the EF-1alpha with the gene number of TGME49286420 is found for the first time in the invention, the expression of the monoclonal antibody in the toxoplasma gondii is very specific, and the toxoplasma gondii can be detected through a Western-blot technology and an indirect immunofluorescence technology.

A genetically modified plant comprising at least one modification from the natively occurring plant, wherein the at least one modification results in overexpression of at least one chloroplastic translation elongation factor-G (EF-G) protein or active fragment thereof. Methods of producing and using the genetically modified plants are also disclosed herein. The genetically modified plants exhibit increased plant biomass, increased yield, and / or increased photosynthetic capacity over a native, non-genetically modified plant.

The present invention relates to methods of determining a potency state of an embryonic stem cell (ESC) in culture, comprising detecting the expression level of Negative Elongation Factor Complex Member A (Nelfa) in the ESC, and correlating the expression level of Nelfa with that of a reference sample to determine the potency state of the ESC. The present invention also provides methods of selecting totipotent-like ESCs from a population of ESCs in culture using an anti-Nelfa antigen binding protein, methods of inducing totipotency in an ESC in culture, methods of improving the reprogramming efficiency of a somatic cell into an induced pluripotent stem cell and methods of reprogramming a somatic cell into a totipotent stem cell by inducing Nelfa expression. Cells comprising an expression vector encoding Nelfa and kits for use in the methods of the invention are also provided.

The present disclosure relates to pharmaceutical compositions comprising a synthetic transcription elongation factor (SynTEF) and an epigenetic inhibitor (e.g., a histone deacetylase (HDAC) inhibitor). As detailed herein, the disclosed compositions and combinations can be used to target FGF14b in Friedreich's ataxia (FRDA / FA), SCA27b, and other GAA-repeat based diseases.

The present disclosure provides DNA molecules, such as transfer plasmids, useful for manufacturing packaged retroviral vectors encoding a therapeutic protein such as chimeric antigen receptors (CARs) and T cell receptors (TCRs). The encoded retroviral transcript in the DNA molecule includes a transgene, an elongation factor 1-alpha 1 (EFla) promoter, without the EFla intron, operably linked to the transgene and a Rev response element (RRE).

A compound derivative is provided, where R in the compound of formula A is piperidine, and the compound derivative can be used in the treatment of cancer and other diseases through the development of small molecules as eukaryotic elongation factor 2 kinase (eEF2K) enzyme inhibitors that are active in breast, pancreatic, brain, ovarian, lung, skin and blood cancers.

A compound derivative is provided, where R in the compound of formula A is (2-(2-(piperidin-1-yl)ethane-1-amine), and the compound derivative can be used in the treatment of cancer and other diseases through the development of small molecules as eukaryotic elongation factor 2 kinase (eEF2K) enzyme inhibitors that are active in breast, pancreatic, brain, ovarian, lung, skin and blood cancers.

To provide a polyisoprenoid production method capable of suitably producing polyisoprenoid even when using a callus.SOLUTION: A method for producing polyisoprenoid comprises using a transformed callus into which a gene encoding a cis-prenyltransferase (CPT) family protein and a gene encoding a Rubber Elongation Factor (REF) family protein are introduced, to produce polyisoprenoid.SELECTED DRAWING: Figure 2

To provide a method for rescuing a termination codon through genetic reassignment using ACE-tRNA.SOLUTION: In certain embodiments, the invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon arm, and an acceptor arm, wherein the T-arm comprises a T-stem having a nucleotide that interacts with elongation factor 1 alpha 1 (EF1 alpha). EF1 alpha recruits aminoacyl-tRNAs to the ribosome and protects the tRNA from being deacylated. Rational nucleotide substitutions result in tuned tRNA: EF1 α interactions that enhance tRNA delivery to the ribosome and protection from de-acylation.SELECTED DRAWING: None

Viral constructs and methods of their use in the treatment of diseases and disorders mediated by reduced ELP1 expression are provided. The viral constructs include a coding sequence for human ELP1 under control of a heterogenous promoter (such as a small nuclear RNA promoter), allowing for an increase in ELP1 protein expression in neuron cells of the central nervous system, including for instance retinal cells. Methods of using such viral constructs to protect neural cells, for instance by reducing death of retinal ganglion cells, are also provided.

The present invention relates to a vaccine composition for preventing malaria, comprising, as an active ingredient, an elongation factor-2 (EF-2) recombinant protein derived from Plasmodium falciparum and, more specifically, to a vaccine composition for preventing malaria, comprising, as an active ingredient, EF-2 recombinant peptides derived from Plasmodium falciparum consisting of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2, respectively, and use thereof.

In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, wherein the T-arm comprises nucleotides that interact with the elongation factor 1 alpha protein, and methods of use thereof. In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, (a) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UCA-3′ and recognizes TGA stop codons, and wherein the acceptor arm is operably linked to a arginine, tryptophan or glycine; (b) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UUA-3′ and recognizes TAA stop codons, and wherein the acceptor arm is operably linked to a glutamine or, glutamate; or (c) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-CUA-3′ and recognizes TAG stop codons, and wherein the acceptor arm is operably linked to a tryptophan, glutamate or glutamine.

Provided herein are recombinant self-complementary adeno-associated virus (scAAV) nucleic acid vectors containing ubiquitous eukaryotic promoters, such as elongation factor 1 alpha (EF1α), chicken beta-actin (CBA), and hybrid chicken beta-actin (CBh), followed by a dominant-negative RhoA. Also provided herein are methods of using the vectors, including intraocular injection (e.g., intracameral injection) to reduce intraocular pressure (IOP). Also provided herein are plasmids, recombinant scAAV particles, compositions, formulations, and other methods of use related to such vectors.

The invention relates to a fusion protein for preventing pathogenic enterococcus infection, an immunogenic composition, a recombinant vaccine, application of the fusion protein, the immunogenic composition and the recombinant vaccine and the like. According to the invention, HlyC / CorC transporter antigens of enterococcus faecium and enterococcus faecalis are selected to construct a fusion protein A, and elongation factor Tu antigens and 50S ribosomal protein L7 / L12 (50S ribosomal protein L7 / L12, rplL) antigens of the enterococcus faecium and the enterococcus faecalis are selected to construct a fusion protein B. According to the present invention, the fusion protein A and the fusion protein B are selected, the vaccine based on the two fusion proteins can significantly weaken tissue infection caused by enterococcus faecium and enterococcus faecalis, has good immunogenicity, plays effective prevention and immune protection roles, can efficiently prevent pathogenic enterococcus infection, and has wide application prospects.

The invention provides bidirectional expression vectors comprising Chinese hamster ovary elongation factor 1-α (CHEF1) transcriptional regulatory DNA elements, a gene of interest (GOI), a minimal cytomegalovirus (minCMV) and a selectable marker (SM) and / or a human adenovirus tripartite leader (AdTPL) sequence. The invention also provides method for increasing heterologous protein expression in a host cell comprising culturing the host cell the bidirectional expression vector(s).

This invention belongs to the fields of plant genetic engineering and biotechnology, and discloses a peanut endogenous strong promoter P. AhEF1α Its preparation methods and applications. Promoters include P AhEF1α‑1 P AhEF1α‑2 P AhEF1α‑3 and P AhEF1α‑4 This invention uses the Arabidopsis EF1α gene amino acid sequence as a reference, identifies candidate peanut EF1α genes through homology search, screens high-expression genes by expression level analysis, and clones the aforementioned promoter from the peanut genome of Yuhua 9326 using PCR technology. A recombinant vector containing this promoter is constructed and transformed into peanut embryogenic callus tissue. Functional verification shows that the promoter can efficiently drive the expression of downstream genes in peanut callus. This invention solves the technical bottleneck of existing peanut gene editing technologies that rely on exogenous promoters and have poor adaptability, fills the gap in the application of strong endogenous promoters in peanuts, and can be used to construct a precise gene editing system for peanuts, promoting stress-resistant, high-quality, and grade-equal peanut varieties. It has significant practical value and industrialization prospects.

The application belongs to the technical field of plant genetic engineering, and particularly relates to an extension factor subunit OsELP4 gene for regulating rice blast resistance and application. An extension factor subunit OsELP4 gene induced by Magnaporthe oryzae is screened, the nucleotide sequence of the gene is shown as SEQ ID NO:1, and the protein sequence coded by the gene is shown as SEQ ID NO:2. By using Agrobacterium-mediated transformation, an OsELP4 overexpression transgenic line and a CRISPR / Cas9 mutant line are obtained. It is found by inoculating and identifying the transgenic materials with rice blast that the OsELP4 overexpression line has enhanced resistance to rice blast, and the mutant line is more susceptible to rice blast, which indicates that OsELP4 is a positive regulation factor for rice resistance to rice blast. OsELP4 plays a positive regulation role in rice resistance to rice blast, and overexpression of the gene can significantly improve the resistance of rice to rice blast.

In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, wherein the T-arm comprises nucleotides that interact with the elongation factor 1 alpha protein, and methods of use thereof. In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, (a) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UCA-3′ and recognizes TGA stop codons, and wherein the acceptor arm is operably linked to a arginine, tryptophan or glycine; (b) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UUA-3′ and recognizes TAA stop codons, and wherein the acceptor arm is operably linked to a glutamine or, glutamate; or (c) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-CUA-3′ and recognizes TAG stop codons, and wherein the acceptor arm is operably linked to a tryptophan, glutamate or glutamine.

The invention provides a genetic expression cassette comprising, in order from 5'-3':an 5' adenoassociated viral (AAV) inverted terminal repeat (ITR), the elongation factor 1 long promoter, a chimeric intron, a 5' UT translational enhancer element containing a Kozak sequence, a polynucleotide comprising a nucleic acid sequence with at least 80% identity to the nucleic acid sequence of either wild-type of propionyl-CoA carboxylase beta (PCCB or synPCCB1), the hepatitis B virus derived post-translational response element, the bovine growth hormone poly-adenylation sequence, and an 3' AAV inverted ITR. The invention also provides expression vectors comprising the inventive cassette, compositions comprising the same, and methods for treating a disease or condition mediated by propionyl-CoA carboxylase.

The application belongs to the technical field of plant genetic engineering, and particularly relates to an extension factor subunit OsRAV9 gene for regulating rice blast resistance and application. An extension factor subunit OsRAV9 gene induced by Magnaporthe oryzae is screened, the nucleotide sequence of the gene is shown as SEQ ID NO:1, and the protein sequence coded by the gene is shown as SEQ ID NO:2. By using Agrobacterium-mediated transformation, an OsRAV9 overexpression transgenic line and a CRISPR / Cas9 mutant line are obtained. It is found by inoculating and identifying the transgenic materials with rice blast that the OsRAV9 overexpression line has enhanced resistance to rice blast, and the mutant line is more susceptible to Magnaporthe oryzae, which indicates that OsRAV9 is a positive regulation factor for rice resistance to rice blast. The OsRAV9 gene plays a positive regulation role in rice resistance to rice blast, and overexpression of the gene can significantly improve the resistance of rice to rice blast.

The application belongs to the technical field of plant genetic engineering, and particularly relates to an extension factor subunit BnELP2 gene for regulating resistance of Brassica napus to sclerotinia stem decay and application. An extension factor subunit BnELP2 gene induced by Sclerotinia sclerotiorum is screened, the nucleotide sequence of the gene is shown as SEQ ID NO:1, and the protein sequence coded by the gene is shown as SEQ ID NO:2. By using Agrobacterium-mediated transformation, a BnELP2 overexpression transgenic line and a CRISPR / Cas9 mutant line are obtained. It is found by inoculating the transgenic material with Sclerotinia sclerotiorum that the BnELP2 overexpression line has enhanced resistance to Sclerotinia sclerotiorum, and the mutant line is more susceptible to Sclerotinia sclerotiorum, which indicates that BnELP2 is a positive regulation factor for resistance of Brassica napus to Sclerotinia sclerotiorum, plays a positive regulation role in resistance of Brassica napus to Sclerotinia sclerotiorum, and overexpression of the gene can significantly improve the resistance of Brassica napus to Sclerotinia sclerotiorum.

The present invention relates to a gene expression cassette including a synthetic 5′ untranslated region (5′ UTR), a promoter, and a regulatory gene; a recombinant vector including a replication origin and the gene expression cassette; a recombinant microorganism which has the recombinant vector introduced thereinto and shows alleviated segregational instability and; a method for preparing a recombinant microorganism having alleviated segregational instability by introducing the recombinant vector thereinto; and a method for quantitatively controlling a plasmid copy number in a recombinant microorganism. According to the present invention, removal of infA and efp, which are genes indispensable for cells, encoding respectively for a translation initiation factor and a protein elongation factor (EF-P), from a microbial chromosome and introduction of the gene expression cassette including the regulatory gene with Escherichia coli serving as a host allow the stable maintenance of plasmids in an antibiotic-free medium without causing intercellular intrinsic variations. In addition, the precise control of expression levels of infA and efp in the recombinant microorganism by means of a promoter can lead to the quantitative control of PCN at high yield as well. Therefore, the present invention can find a broad spectrum of applications in a variety of industries producing recombinant proteins.

The invention discloses a pathogen infection diagnosis marker based on DPH gene family mRNA and diphtheria amide modification level, a kit and application. The marker combination comprises the mRNA expression level of the DPH1-DPH7 gene and the diphtheria amide modification level of the eukaryotic elongation factor 2. The invention reveals that the combination is remarkably related to pathogen infection for the first time, and provides a detection kit containing a specific primer, biotinylated NAD, pseudomonas exotoxin A and other reagents. The indexes are respectively detected through qPCR (quantitative polymerase chain reaction) and non-denatured immunoblotting, and efficient diagnosis can be realized through combined analysis. Experiments show that the combined marker is excellent in diagnostic performance, the area AUC under a curve of a combined logistic regression model can reach 0.917, the sensitivity is 90.9%, the specificity is 85.7%, and a novel and reliable molecular scheme is provided for early-stage differential diagnosis of infection.

The present disclosure provides DNA molecules, such as transfer plasmids, useful for manufacturing packaged retroviral vectors encoding a therapeutic protein such as chimeric antigen receptors (CARs) and T cell receptors (TCRs). The encoded retroviral transcript in the DNA molecule includes a transgene, an elongation factor 1-alpha 1 (EF1α) promoter, without the EF1α intron, operably linked to the transgene and a Rev response element (RRE).

A compound derivative is provided, where R in the compound of formula A is 4-methylpiperazine, and the compound derivative can be used in the treatment of cancer and other diseases through the development of small molecules as eukaryotic elongation factor 2 kinase (eEF2K) enzyme inhibitors that are active in breast, pancreatic, brain, ovarian, lung, skin and blood cancers.

The present invention relates to a method for rescuing termination codons via genetic redistribution using ACE-tRNA. The present invention relates to a method for rescuing termination codons via genetic redistribution using ACE-tRNA. Specifically, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon arm, and a receptor arm, where the T-arm comprises a nucleotide that interacts with an elongation factor 1 [alpha] protein, and methods of use thereof.